Halozyme Therapeutics Inc., of San Diego, said the European Commission has approved the subcutaneous formulation of Mabthera (rituximab) from Basel, Switzerland-based Roche AG for treating patients with follicular lymphoma and diffuse large B-cell lymphoma.